Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery
Status: | Active, not recruiting |
---|---|
Conditions: | Infectious Disease |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - 80 |
Updated: | 11/7/2018 |
Start Date: | June 2013 |
End Date: | October 2019 |
Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery (OXYGEN Study)
The OXYGEN Study is a double blinded prospective randomized controlled trial that will
compare the proportion of surgical site infections within 6 months in patients treated with
Supplemental Perioperative Oxygen compared to those treated without Supplemental
Perioperative Oxygen.
compare the proportion of surgical site infections within 6 months in patients treated with
Supplemental Perioperative Oxygen compared to those treated without Supplemental
Perioperative Oxygen.
Primary Objective
To compare the proportion of surgical site infections within 6 months in patients treated
with Supplemental Perioperative Oxygen compared to those treated without Supplemental
Perioperative Oxygen.
Secondary Objectives
To compare species and antibacterial sensitivities of the bacteria in the patients who
develop surgical site infections in study patients treated with Supplemental Perioperative
Oxygen compared to those treated without Supplemental Perioperative Oxygen.
To validate the previously developed risk prediction model for the development of surgical
site infections after fracture surgery
To measure and compare resource utilization and cost associated with surgical site infection
in study patients treated with Supplemental Perioperative Oxygen compared to those treated
without Supplemental Perioperative Oxygen.
Primary Aim: To compare the proportion of surgical site infections within 6 months in
patients treated with Supplemental Perioperative Oxygen compared to those treated without
Supplemental Perioperative Oxygen.
Hypothesis 1: The proportion of surgical site infections will be lower for patients treated
with Supplemental Perioperative Oxygen.
Secondary Aim #1: Compare bacterial species and antimicrobial susceptibilities in the
patients who develop surgical site infections in study patients treated with Supplemental
Perioperative Oxygen compared to those treated without Supplemental Perioperative Oxygen.
Hypothesis 2: In the patients who develop infections, the bacterial species and antimicrobial
susceptibility profiles of those treated with Supplemental Perioperative Oxygen will be
similar to those treated without Supplemental Perioperative Oxygen.
Secondary Aim #2: To validate the previously developed risk prediction model for the
development of surgical site infections after fracture surgery.
Hypothesis 3: The previously developed RIOTS score will be highly predictive of infection
risk.
Secondary Aim #3: Measure and compare resource utilization and cost associated with surgical
site infection in study patients treated with Supplemental Perioperative Oxygen compared to
those treated without Supplemental Perioperative Oxygen.
Hypothesis 4: Supplemental Perioperative Oxygen will be associated with lower resource
utilization and cost.
To compare the proportion of surgical site infections within 6 months in patients treated
with Supplemental Perioperative Oxygen compared to those treated without Supplemental
Perioperative Oxygen.
Secondary Objectives
To compare species and antibacterial sensitivities of the bacteria in the patients who
develop surgical site infections in study patients treated with Supplemental Perioperative
Oxygen compared to those treated without Supplemental Perioperative Oxygen.
To validate the previously developed risk prediction model for the development of surgical
site infections after fracture surgery
To measure and compare resource utilization and cost associated with surgical site infection
in study patients treated with Supplemental Perioperative Oxygen compared to those treated
without Supplemental Perioperative Oxygen.
Primary Aim: To compare the proportion of surgical site infections within 6 months in
patients treated with Supplemental Perioperative Oxygen compared to those treated without
Supplemental Perioperative Oxygen.
Hypothesis 1: The proportion of surgical site infections will be lower for patients treated
with Supplemental Perioperative Oxygen.
Secondary Aim #1: Compare bacterial species and antimicrobial susceptibilities in the
patients who develop surgical site infections in study patients treated with Supplemental
Perioperative Oxygen compared to those treated without Supplemental Perioperative Oxygen.
Hypothesis 2: In the patients who develop infections, the bacterial species and antimicrobial
susceptibility profiles of those treated with Supplemental Perioperative Oxygen will be
similar to those treated without Supplemental Perioperative Oxygen.
Secondary Aim #2: To validate the previously developed risk prediction model for the
development of surgical site infections after fracture surgery.
Hypothesis 3: The previously developed RIOTS score will be highly predictive of infection
risk.
Secondary Aim #3: Measure and compare resource utilization and cost associated with surgical
site infection in study patients treated with Supplemental Perioperative Oxygen compared to
those treated without Supplemental Perioperative Oxygen.
Hypothesis 4: Supplemental Perioperative Oxygen will be associated with lower resource
utilization and cost.
Inclusion Criteria:
- All "high energy" tibial plateau fractures treated operatively with plate and screw
fixation. We define "high energy" tibial plateau fractures as patients who are either:
- Initially treated with an external fixation and treated more than 7 days later
after swelling has resolved.
- Gustilo Type I, II, and IIIA open fracture, regardless of timing of definitive
treatment.
- All "high energy" pilon (distal tibial plafond) fractures treated operatively with
plate and screw fixation. We define "high energy" tibial plateau fractures as patients
who are either:
- Initially treated with an external fixation (with or without fibula fixation or
limited internal fixation) and treated definitively more than 7 days later after
swelling has resolved.
- Gustilo Type I, II, and IIIA open fracture, regardless of timing of definitive
treatment.
- All "high energy" calcaneus fractures treated operatively with plate and screw
fixation in a staged fashion. We define "high energy" calcaneus fractures as patients
who are either:
- Treated definitively more than 7 days later after swelling has resolved.
- Gustilo Type Type I, II, and IIIA [30,31] open fracture, regardless of timing of
definitive treatment.
- Ages 18 to 80 years
- Patients may have co-existing infection not at study fracture site, with or without
antibiotic treatment.
- Patients may have risk factors for infection including diabetes, immunosuppression
from steroids or other medications, HIV, or other infections.
- Patients may have a head injury.
- Patients may be treated initially with a temporary external fixator prior to
randomization.
- Patients may have a portion of the fixation (e.g. fibula fixation in pilon or
percutaneous screws across a tibial plateau fracture) prior to definitive plate
fixation, at any initial surgery before randomization for definitive fixation.
- Patients may have other orthopedic and non-orthopaedic injuries.
- Patients may have pre-existing musculoskeletal injuries, be non ambulators, or have
spinal cord injuries.
Exclusion Criteria:
- Tibial plateau, pilon, or calcaneus already infected at time of study enrollment.
- Type IIIB, or IIIC open [30,31] fractures
- Patient speaks neither English nor Spanish.
- Transfer patients who have already had definitive fixation.
- Severe problems with maintaining follow-up (e.g. patients who are homeless at the time
of injury or those how are intellectually challenged without adequate family support).
- Patients who are intubated at the time of consent.
- Patients whose oxygen requirements at the time of surgery would prevent them from
participating in either study group will be excluded.
- History of COPD or any other chronic respiratory disease that renders the patient
oxygen dependent at baseline.
- Current or history of Bleomycin use (chemotherapy use associated with oxygen
toxicity).
- Patient is currently pregnant.
We found this trial at
2
sites
Phoenix, Arizona 85023
Principal Investigator: Clifford Jones, MD
Click here to add this to my saved trials
Baltimore, Maryland 21201
Principal Investigator: Robert O'Toole, MD
Click here to add this to my saved trials